Glycovax-002 is under clinical development by Glycovax Pharma and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Glycovax-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Glycovax-002 overview
Glycovax-002 is under development for the prevention of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is a semi-synthetic, glycoconjugate vaccine and developed based on glyconanotechnology. It is administered through intramuscular route.
Glycovax Pharma overview
Glycovax Pharma (Glycovax) develops drugs and new therapeutic strategies utilizing the power of medical nanotechnology for the treatment of cancers and infectious diseases. The company designed a nanomedicine technology platform based on new class of synthetic nanoparticles to develop simplified diagnostic tools and semi-synthetic vaccines to prevent and treat breast cancers and several other infectious pathologies. It seeks to reduce side effects of therapeutic agents and facilitate the production of high quality innovative drugs in the pharmaceutical industry. The company conducts its research activities combining nanotechnology with glycobiology to design novel functional bionanomaterials. Glycovax is headquartered in Montreal, Quebec, Canada.
For a complete picture of Glycovax-002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
